TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2442560
Drug: Lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5 mg daily (with option to increase to 10 or 20 mg)
Study: 23385792
Drug: Lutein supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplementation (10 mg Ester daily)
Study: 23385792
Drug: Lutein supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplementation (10 mg Ester daily) in subgroup (n = 19)
Study: 19077388
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral pyridoxine thrice daily
Study: 16148965
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group received the 2000 version of the Medicare & You handbook; control group received no Medicare-related information.
Study: 8359565
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of Sandostatin (SMS)
Study: 2444797
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg twice daily for 8 weeks)
Study: 11456286
Drug: Gliclazide 160
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 160 mg
Study: 30208070
Drug: Symptom-guided treatment
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-guided treatment (Control)
Study: 24797121
Drug: Low-dose opioid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose opioid regimen (remifentanil effect-site concentration half of propofol)
Study: 24797121
Drug: High-dose opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose opioid regimen (remifentanil effect-site concentration double that of propofol)
Study: 17634269
Drug: Medox (anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medox (anthocyanin supplementation, 300 mg/d for 3 weeks)
Study: 7665416
Drug: Added fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Added fat and protein (FP) diet (C diet + 1.6 g.kg‐1.day‐1 fat + 1.2 g.kg‐1.day‐1 protein)
Study: 7665416
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) diet (high glycemic index CHO foods; CHO = 7 g.kg‐1.day‐1)
Study: 7665416
Drug: Matched-energy diet
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched-energy diet (C diet + 4.8 g.kg‐1.day‐1 additional CHO)
Study: 25203688
Drug: 39 g·hr(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 39 g·hr(‐1) carbohydrate (CHO)
Study: 25203688
Drug: 64 g·hr(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 g·hr(‐1) carbohydrate (CHO)
Study: 25203688
Drug: 20 g·hr(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g·hr(‐1) carbohydrate (CHO)
Study: 25203688
Drug: 0 g·hr(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g·hr(‐1) control (water)
Study: 12590356
Drug: Risperidone 2-6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2-6 mg/day
Study: 12590356
Drug: Olanzapine 5-20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5-20 mg/day
Study: 10565798
Drug: Amitriptyline (50-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50-250 mg/day, mean 138.1 mg/day)
Study: 6136695
Drug: Combination cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cytotoxic chemotherapy (intravenous cyclophosphamide, methotrexate, and fluorouracil)
Study: 6136695
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy or conventionally timed chemotherapy
Study: 31493951
Drug: AdtFMD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdtFMD vaccine (commercial vaccine vector expressing capsid proteins of FMDV strain A24 Cruzeiro)
Study: 27481104
Drug: Personalized exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized exercise prescription (intensity that 'feels good' to the individual for 8 weeks during daily Physical Education)
Study: 27481104
Drug: Moderate-intensity exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity exercise prescription (target heart rate range 60-80% of HR max for 8 weeks during daily Physical Education)
Study: 22495590
Drug: Sympathetic inhibition
Normalized name: Bos taurus sympathetic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sympathetic inhibition via clonidine (48 h transdermal administration) during hypoxia
Study: 12452301
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg twice daily by SC injection)
Study: 12452301
Drug: Dalteparin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (120 IU/kg twice daily by SC injection)
Study: 9607384
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tasosartan
Study: 9607384
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg tasosartan
Study: 9607384
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tasosartan
Study: 9607384
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tasosartan
Study: 8169569
Drug: Choice between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice between previously sampled doses (0.0%, 2.0%, and 3.5%)
Study: 31497988
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol administration (exact dosage not specified)
Study: 31497988
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol administration
Study: 19648776
Drug: 5% dexpanthenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dexpanthenol ointment
Study: 19648776
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (vehicle without dexpanthenol)
Study: 11379804
Drug: Intranasal IL-6
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal IL-6 (0, 0.01, 0.1, and 1 microg/mL)
Study: 9224439
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment emphasizing patient pleasant events
Study: 9224439
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment emphasizing caregiver problem solving
Study: 3611398
Drug: Lorazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (4 mg orally)
Study: 2667015
Drug: Desmethylimipramine (DMI)
Normalized name: Desmethylimipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desmethylimipramine (DMI) 50 mg oral test dose
Study: 31520258
Drug: No acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acupuncture therapy (Control)
Study: 21702877
Drug: Infant massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant massage intervention (daily for 10 weeks)
Study: 9386211
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined HRT with Kliogest (daily tablet for 9 months)
Study: 7952793
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 12.5, 50 and 100 micrograms
Study: 7952793
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 50 and 100 micrograms
Study: 7952793
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol and salbutamol
Study: 2438095
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol and theophylline
Study: 26397235
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (1.5 mg/kg IV bolus followed by 2 mg/kg/h infusion until end of surgery)
Study: 24534082
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise program (12-week, thrice weekly)
Study: 22948049
Drug: Stanford V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanford V chemotherapy
Study: 20063935
Drug: Cognitive function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive function assessment (not specified dosage or duration)
Study: 15694083
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 25 microg every 3 days for a maximum of three doses
Study: 15694083
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 50 microg every 3 days for a maximum of three doses
Study: 12798694
Drug: RT (Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT (Radiation Therapy)
Study: 12798694
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + HYST (Radiation Therapy with Extrafascial Hysterectomy)
Study: 10365928
Drug: Topical azelaic
Normalized name: azelaic acid Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical azelaic acid 20% cream
Study: 10365928
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole 0.75% cream
Study: 6756934
Drug: Piretanide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 1.0 mg
Study: 6756934
Drug: Frusemide 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 6.25 mg
Study: 24743706
Drug: Experimental therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapies (specific therapies not detailed)
Study: 24743706
Drug: FOLFIRI chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI chemotherapy (common control arm)
Study: 23890766
Drug: Asthma Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma Therapy Assessment Questionnaire (ATAQ)
Study: 17975232
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with meperidine (2 mg/mL) + adrenaline (2 µg/mL)
Study: 17975232
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with meperidine (2 mg/mL) alone
Study: 15125570
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid in the tablet matrix (10-15%)
Study: 15125570
Drug: Ibuprofen (model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (model drug)
Study: 7637825
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) and chemotherapy (ChT) containing cisplatinum and 5-fluorouracil (5-FU)
Study: 880567
Drug: Methotrexate high
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate high dose (0.06 mg/kg/dose)
Study: 880567
Drug: Methotrexate low
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate low dose (0.2 mg/kg/dose)
Study: 880567
Drug: Methotrexate high
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate high dose and low dose
Study: 25240629
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid eye drops (0.5% loteprednol etabonate) 4 times daily for 15 days
Study: 22829151
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment as usual, N = 13)
Study: 17464237
Drug: Isoflavone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone (75 mg of isoflavone conjugates/day)
Study: 10229408
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release oxycodone
Study: 9646650
Drug: Nasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal ketamine 0.25 mg/kg
Study: 9646650
Drug: Nasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal ketamine 5 mg/kg
Study: 8709686
Drug: AZT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT plus ddl (400 mg per day)
Study: 8709686
Drug: AZT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT plus ddC (2.25 mg per day)
Study: 8709686
Drug: AZT (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT (600 mg per day) alone
Study: 2321571
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1500 mg total, three times daily with meals for 5.5 weeks)
Study: 25471276
Drug: Additional androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional androgen deprivation therapy (ADT)
Study: 19587642
Drug: CP‐800,569 (30‐1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐800,569 (30‐1,800 mg once daily for 14 days)
Study: 19587642
Drug: CP‐800,569 (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐800,569 (1,800 mg)
Study: 19587642
Drug: CP‐800,569 (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐800,569 (higher doses)
Study: 1467292
Drug: Acitretin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (50 mg/day)
Study: 26525882
Drug: Standard nCPAP-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nCPAP-titration
Study: 22990619
Drug: Dextromethorphan (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (60-120 mg/day)
Study: 19781131
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100 microg or 4000 IU daily for 6 months)
Study: 15906590
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation of bupropion in fasting state
Study: 15906590
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation of bupropion after high fat meal
Study: 11872895
Drug: Abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus of 0.25 mg/kg body weight
Study: 11872895
Drug: Standard antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antithrombotic medication (aspirin, clopidogrel, and heparin) without abciximab
Study: 26314508
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive remediation therapy (CRT), 40 sessions
Study: 26314508
Drug: Musical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musical and Dancing Therapy (MDT), therapeutic contact-matched
Study: 26314508
Drug: Musical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musical and Dancing Therapy (MDT)
Study: 11293557
Drug: Encapsulated 50-mg
Normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated 50-mg sumatriptan tablets
Study: 11293557
Drug: Conventional 50-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 50-mg sumatriptan tablets
Study: 8071850
Drug: Butorphanol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0, 0.5, 1.0 or 2.0 mg/70 kg)
Study: 8071850
Drug: Both butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both butorphanol and morphine
Study: 28479216
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy and Holistic Health Recovery Program for Malaysia (HHRP-M)
Study: 28479216
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy alone
Study: 22119148
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS)
Study: 17663102
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Duxil (control group)
Study: 16135001
Drug: Specific oral
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific oral tolerance induction (SOTI) treatment with a maximum dose of 250 ml cow's milk or 4.5 g lyophilized hen's egg protein; daily maintenance dose of 100 ml cow's milk or 2.5 g hen's egg protein
Study: 16135001
Drug: SOTI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOTI treatment
Study: 2222246
Drug: GM-1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-1 treatment (100 mg by daily intramuscular injection for 12 weeks)
Study: 22759327
Drug: Lafutidine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine at 10 mg t.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (LFT-AM)
Study: 22759327
Drug: Rabeprazole at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole at 10 mg b.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (RPZ-AM)
Study: 19339001
Drug: Mixed (M)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed (M) group: rFSH and cetrorelix mixed immediately before administration
Study: 19339001
Drug: Separate (S)
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate (S) group: rFSH and cetrorelix administered separately
Study: 18844696
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg CP‐481715 TID
Study: 18844696
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg CP‐481715 QD
Study: 11923586
Drug: Metadoxine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metadoxine (900 mg intravenous)
Study: 10373342
Drug: biosynthetic GH
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biosynthetic GH 2 IU/m2 s.c. daily (n=13)
Study: 18410864
Drug: lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam 8 mg (twice daily)
Study: 18410864
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg (twice daily)
Study: 18410864
Drug: ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 100 mg (twice daily)
Study: 18410864
Drug: dipyrone 1
Normalized name: dipyrone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dipyrone 1 g (three times daily)
Study: 18410864
Drug: placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (twice daily)
Study: 10450449
Drug: Mebendazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (single 500 mg dose)
Study: 10450449
Drug: Pyrantel (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel (single dose 12.5 mg/kg bodyweight)
Study: 2467982
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg twice a day for 4 days
Study: 28315319
Drug: Subcutaneous IFN‐α2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFN‐α2a
Study: 23266342
Drug: Intramuscular MVA85A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular MVA85A
Study: 23266342
Drug: Intradermal MVA85A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal MVA85A
Study: 21923715
Drug: Mesalazine granules
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine granules (3 g/day, 3 g once daily or 1 g three times daily)
Study: 21923715
Drug: Mesalazine granules
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine granules (3 g/day)
Study: 21923715
Drug: Mesalazine granules
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine granules (once daily)
Study: 21923715
Drug: Mesalazine tablets
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine tablets (3 g/day, 1 g three times daily)
Study: 20027354
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens extract (reference preparation)
Study: 17099030
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin solution with oral ciprofloxacin
Study: 17099030
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with oral ciprofloxacin
Study: 3227053
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg (single dose)
Study: 3227053
Drug: Rolipram 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolipram 0.75 mg (multiple dosing every 8 hours for 5 days)
Study: 3227053
Drug: Rolipram 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolipram 1.5 mg (multiple dosing every 8 hours for 5 days)
Study: 3227053
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (single dose)
Study: 21401351
Drug: Articaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine (40 mL of articaine HCI 20 mg/mL with 2 mL isotonic sodium chloride solution)
Study: 21401351
Drug: Articaine-fentanyl (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine-fentanyl (40 mL of articaine HCI 20 mg/mL with 2 mL (100 µg) of fentanyl)
Study: 18368615
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg nocte for 2 days, 30 mg nocte for 12 days)
Study: 16988084
Drug: Tailored weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored weight management intervention (6 monthly outpatient visits, 15 minutes each)
Study: 10749622
Drug: Sequential GM‐CSF/bFGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential GM‐CSF/bFGF therapy